Clinical trial
Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual…
NCT00434629 · University of Pennsylvania, Other · Completed
Key facts
| NCT number | NCT00434629 |
|---|---|
| Title | Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant |
| Official title | A Phase I Study of Bexxar® (Tositumomab and 131I-Tositumomab) Radioimmunotherapy in Patients With Relapsed or Residual CD20 Antigen-Expressing B-Cell Lymphomas Following Autologous Hematopoietic Stem Cell Transplantation |
| Lead sponsor | University of Pennsylvania, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | B-cell Lymphoma, Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Bexxar |
| Enrollment | 16 |
| Start date | Feb 1, 2007 |
| Primary completion | May 1, 2015 |
| Completion | May 1, 2015 |
| First posted | Feb 13, 2007 |
| Last update posted | Aug 17, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: